Abstract
INTRODUCTION
Lung transplantation remains the only therapeutic option associated with both improved quality of life and chances of survival for patients with end-stage lung disease [1] . Despite improving results, these procedures are limited by the shortage of available and suitable donor lungs.
The Lung Allocation Score (LAS) was first implemented in Germany in December 2011, replacing an allocation system based on urgency status and accumulated waiting time. The LAS distributes donor lungs to patients who have the highest predicted risk of death on the waitlist and, at the same time, the best survival probability 1 year after transplantation [2] . Lungs are, therefore, allocated preferably to patients in critical conditions, thereby successfully decreasing pretransplant mortality and reducing overall waiting time [3] .
Several centres, including our own, have shown favourable effects of the LAS on waitlist survival and improved post-transplant outcomes since its implementation in 2011 [4] [5] [6] . The latter promising data, however, represent only a short-term follow-up of up to 3 years after changing the allocation system. It is, therefore, of paramount importance to repetitively update the experiences with the novel allocation system for continuous validation of efficient and adequate organ allocations within the influential area of the Eurotransplant Foundation (ET). Despite these more global aspects, centre-specific lung transplant policies and activities have to be recognized.
This study aims to report our high-volume single-centre experience with the LAS 5 years after its implementation.
METHODS

Patients
We retrospectively analysed data of patients listed for and receiving a lung transplant between December 2011 and December 2016. Data were analysed differentially according to underlying pulmonary diagnosis: obstructive lung disease, e.g. chronic obstructive pulmonary disease (COPD) or emphysema; interstitial lung disease (ILD), e.g. idiopathic pulmonary fibrosis; cystic fibrosis (CF) and others, e.g. sarcoidosis or primary pulmonary hypertension. Additional distinctions were made based on the type of procedure, i.e. a single-lung transplantation (SLTX) or bilateral sequential lung transplantation (BLTX); the LAS category, i.e. low-LAS <50 or high-LAS > _50; the type of organ offer, i.e. the primary LAS-based or LAS-independent competitive organ offer. Of note, the ET intends to distribute all organs following the patient ranking of the LAS. Organs, which cannot be allocated using this LAS-dependent manner, are offered in a competitive, non-LAS-dependent fashion to all centres at the same time and are distributed to a patient of the first accepting centre. Multiorgan recipients were excluded from our analysis.
Parameters
Waitlist characteristics were analysed point by point at the end of each year between 2011 and 2016. Such data comprise the waiting times and overall mean LAS values of listed patients at the indicated time points. Cumulative waitlist characteristics represent death rates and numbers of high-LAS candidates per year.
Outcome parameters comprise survival probability up to 5 years after transplant, the LAS values at the time of transplantation, duration of post-transplant mechanical ventilation, intensive care unit (ICU) and hospital stay, need and duration of post-transplant extracorporeal circulatory support.
The clinical status of waiting and transplanted patients were regularly reviewed by the institutional multidisciplinary conference of the Munich Lung Transplant Group (MLTG), consisting of pneumologists, cardiac and thoracic surgeons, anaesthesiologists, intensive care physicians and representatives of affiliated hospitals. The local ethics committee approved the analysis.
Statistics
Data are presented as mean values ± standard deviation, and n represents the number of patients per group. Continuous variables are compared using the Student's t-test or the MannWhitney U-test, depending on data distribution followed by adequate post hoc testing when comparing more than 2 groups. Categorical data are expressed as frequency or percentage and are analysed using the v 2 test. The univariate analysis and the multivariate Cox proportional hazards logistic regression method are used to estimate odds ratio and 95% confidence interval of risk factors associated with overall mortality.
Post-transplant survival probabilities are analysed using the Kaplan-Meier method. Differences in survival between groups are compared using the log-rank test.
A P-value of <0.05 is considered statistically significant. Data analysis and graphics are performed using the R Statistical Software R 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS version 23.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Waitlist characteristics
A total of 377 patients were newly listed for lung transplantation after the LAS implementation in December 2011 until the end of 2016. Thirty-eight patients were on the waitlist when the LAS system was introduced on 10 December 2011. Their clinical profiles were translated into the LAS according to the Eurotransplant business rules. Tables 1 and 2 depict the waitlist characteristics of lung transplant candidates. COPD patients were the largest patient group on the waitlist during the entire observation period ( Table 1 ). The proportion of COPD patients varied over time between approximately 40% and 53% in 2011 and 2016, respectively. The relative numbers of waiting ILD and CF patients were roughly comparable and stable (Table 1) .
We noted a reduction in the overall mean LAS in lung transplant candidates over the years. The mean LAS of lung transplant candidates was 38.1 ± 7.4 at the end of 2011 and decreased throughout the study to 33.9 ± 3.1 at the end of 2016. The decrease over the years was statistically not significant (P = 0.543; Table 1 ). However, the decrease in the mean overall LAS values was not attributable to the increasing numbers of waiting COPD patients. The LAS values of waiting candidates similarly decreased within the different patient groups ( Table 2 ).
The LAS values of candidates differed between the candidate groups, depending on the underlying pulmonary diagnosis. As such, COPD patients were more likely to have lower LAS scores than patients with ILD, who demonstrated the highest LAS values of all subgroups (32.4 ± 1.1 vs 36.2 ± 4.6 in 2016; P = 0.264) ( Table 2) .
The overall waitlist mortality from 2012 to 2016 was 12.4%. During 2012, 5 patients died while waiting for a transplant and 7 during 2016. There was no significant change in waitlist deaths per year during the observation period of 5 years. In total, 47 patients died while on the waitlist or were too critically ill for transplantation and consequently delisted. A total of 294 patients were transplanted.
Transplanted patients
A total number of 294 patients underwent SLTX or BLTX at our centre for end-stage lung disease between 10 December 2011 and the end of 2016. A total number of 140 recipients (48%) were female. Overall, the mean age at the time of transplantation was 50 ± 13 years. The annual number of lung transplant procedures performed was 73 in 2012, 57 in 2013, 57 in 2014, 37 in 2015 and 63 in 2016 (Table 3 ). The underlying pulmonary diagnoses leading to transplantation were ILD in 110, CF in 87 and COPD in 72 patients. Other diagnoses lead to transplantation in 25 patients (Table 4) .
The waiting times of transplanted patients were generally heterogeneous. The overall mean time between admission on the waiting list and transplantation was 207 ± 386 days (range 1-2849 days). The waiting times decreased over the observation period within the groups of transplanted ILD and COPD patients (Table 4) . Generally, transplanted ILD and CF patients exhibited relatively short waiting times when compared with COPD patients, but all the differences were statistically not significant (P = 0.37, P = 0.32; Table 4 ).
The overall mean pretransplant LAS was 47.6 ± 16.2. Patients with CF presented with the highest LAS values at the time of transplantation, i.e. 52.3 ± 15.8, whereas transplanted COPD patients had the lowest LAS values at the time of transplantation, i.e. 35.8 ± 6.1 (P < 0.001).
We noted a change in indications for lung transplantation over time. There was a relative increase in lung transplants performed in ILD patients over the period of 5 years (P = 0.056). In comparison with 27% in 2012, the number of transplantations performed for ILD nearly doubled. In 2016, ILD accounted for 54% and thus has become the most frequent indication for lung transplantation at our centre (Table 3) .
In contrast, the proportion of patients with COPD undergoing lung transplantation decreased from 29% in 2012 to 19% in 2016 (P = 0.029), although representing the most common underlying diagnosis on the waitlist in 2016 (Table 1) . Interestingly, the proportion of lung transplants performed in CF patients also slightly decreased over time from 33% in 2012 to 21% in 2016 (Table 3) , despite the relatively high-LAS values in patients with CF at the time of transplantation. The decrease over time, however, was not statistically significant (P = 0.31).
Outcome
There was no statistically significant difference in survival probabilities when stratifying patients according to their underlying Table 2 : The LAS of patients on the waitlist for lung transplantation stratified by underlying diagnosis ILD, mean ± SD COPD, mean ± SD CF, mean ± SD Others, mean ± SD 2011 47.7 ± 9.4 (n = 10) 34.6 ± 3.2 (n = 18) 40.7 ± 8.6 (n = 13) 40.7 ± 11.6 (n = 3) 2012 44.3 ± 17.9 (n = 9) 34.9 ± 2.3 (n = 14) 38.6 ± 3.5 (n = disease (P = 0.16; Fig. 1 ). The Kaplan-Meier estimation predicted a survival rate 4 years after LTX of 67% in ILD, 71% in COPD, 79% in CF and 62% in others. Table 5 demonstrates the results of the univariate analysis of risk factors for post-transplant mortality. BLTX was associated with highly significantly increased longterm survival probability when compared with SLTX (P < 0.001), as shown in the Kaplan-Meier survival curve (Fig. 2) . The multivariate analysis confirmed that SLTX was associated with higher mortality (odds ratio 3.78; confidence interval 1.95-7.31; P < 0.001). Survival in BLTX was superior to SLTX at all time points beyond the 2 years examined (3 years: 87% vs 80%; 4 years: 77% vs 59% and 5 years: 51% vs 15%). Thirty-eight percent of SLTXs were performed on patients with COPD as the underlying diagnosis and 40% in ILD patients. The majority (57%) of patients with COPD received an SLTX. It has to be noted that SLTX and BLTX recipients differed concerning age (59 ± 6 vs 46 ± 13 years; P < 0.001), the LAS at the time of transplantation (44 ± 15 vs 49 ± 16; P = 0.027) and overall waiting times (171 ± 407 vs 223 ± 376 days; P = 0.21).
A high LAS, i.e. an LAS > _ 50, was found in 78 (26%) of transplanted patients. When survival probabilities were differentially analysed dividing the transplanted patients into a high-LAS group (LAS > _ 50) and a low-LAS group (LAS < 50), overall survival between these 2 groups was not significantly different (P = 0.81). ILD was the predominant diagnosis in the high-LAS group, represented in 47% of patients transplanted with a high LAS. COPD was only represented in 1 (1%) patient in the high-LAS group. Transplanted CF patients had a high LAS in 32 cases (41%).
Overall, 65 (22%) patients received lungs following competitive organ offers, i.e. independent of the LAS. Those organs were offered, when regular, LAS-based allocation did not result in acceptance. Transplantations following such competitive organ offers were not associated with increased mortality when compared with primary, LAS-based organ offers (P = 0.11). The majority of lung transplants following competitive organ offers were performed on 33 (51%) patients with COPD, whereas only 19 (29%) and 9 (14%) were transplanted in ILD and CF patients, respectively. Within the different disease entity groups, 17% of ILD patients, 10% of CF patients and 46% of COPD patients received a competitive organ offer. The overall mean length of hospital stay for all transplanted patients was 57 ± 48 days and the overall mean length of stay in the ICU was 28 ± 48 days. Mean overall post-transplant need for mechanical ventilation was 578 ± 1357 h. Disease-specific postoperative hospital and ICU stays and ventilation times are depicted in Table 6 . ICU and hospital stays as well as duration of mechanical ventilator support were longer in patients with CF, when compared with patients with ILD or COPD. Extracorporeal membrane oxygenation support was used postoperatively in 54 (18%) patients.
DISCUSSION
The LAS was first introduced in the USA in 2005, replacing an allocation system based on waiting time only [2] . Before the introduction of the LAS, lung transplant candidates were listed at very early stages of the underlying disease. Hence, there was relatively high waitlist mortality, particularly in patients with a rapidly declining clinical status, such as ILD patients [2] . In fact, ILD patients had the highest waitlist mortality, and the likelihood of transplantation was the best for patients with COPD [7] .
In Germany, the LAS replaced an allocation system based on both urgency status and waiting time. It is, therefore, obvious that changes in lung allocation under the LAS cannot be directly compared between Germany and the USA. Although the German and American pre-LAS allocation systems were not comparable, it is interesting to note that patients with COPD were also allocated lungs most frequently in Germany before the LAS implementation, similar to the pre-LAS era in the USA [6] . Although urgency had already been acknowledged, the pre-LAS system in Germany neglected the prospective transplantation benefit that was demanded by the German legislation for organ transplantation. The implementation of the LAS now allows lung allocation to patients with both the most critical clinical condition and the best prospective transplantation benefit, i.e. the greatest calculated likelihood of surviving 1 year after transplantation.
The main objectives of the LAS were, therefore, to improve overall transplant benefit with the main emphasis on reducing waitlist mortality [2] .
Twelve years after introduction of the LAS system, results from large cohort studies in the USA using the united network for organ sharing (UNOS) database have shown mostly favourable outcomes, especially concerning waitlist survival [4, 8] . However, data outside of the USA are very limited, and to date, there is no European study presenting outcomes beyond 3 years after implementation of the LAS [6] . The emerging question is whether promising results from national databases in the USA are reproducible in Germany, especially since our pretransplant system, which attaches more weight to high-urgency status than sole waiting list time, already incorporated life-threatening clinical statuses.
In our study, we, therefore, present the results of a highvolume transplant centre and sought to evaluate the impact of the LAS on waitlist and overall post-transplant outcomes by presenting long-term outcomes of up to 5 years. This is important considering tremendous heterogeneity between the German lung transplant programmes in terms of transplant activity (volume), listing criteria and operative procedures in pre-, intra-and post-transplant patient management.
The main intention of LAS implementation was to benefit patients with the highest likelihood of mortality while waiting for a transplant. Several studies confirmed that the LAS favours patients with an underlying diagnosis consistent with the highest waitlist mortality before implementation, that is, idiopathic pulmonary fibrosis [2, 4] . In our cohort, we confirm that over the period of 5 years, patients with ILD were transplanted with progressive frequency. This documents that the LAS is a powerful tool accommodating disease status and post-transplant survival accurately. However, prioritizing patients with ILD under the LAS may adversely affect patients with other diseases, for example, COPD. In fact, we and others noted a decline in the number of patients transplanted for COPD over time [6] . Further evaluation of the LAS will raise the question as to whether transplant benefit may remain to be defined as calculated 1-year survival or whether aspects of life quality have to be considered as well.
Herein, patients with COPD were more likely to receive lung transplants from the LAS-independent competitive organ offers. As competitive organ offers were not associated with higher mortality, when compared with the LAS-dependent primary organ offers, acceptance of competitive organ offers remains a Figure 2 : The Kaplan-Meier survival estimate after lung transplantation stratified by underlying procedure (DLTX vs SLTX). A significant difference in survival between DLTX and SLTX was found (P < 0.001, the log-rank test). DLTX: double lung transplantation; SLTX: single-lung transplantation. valid option for COPD patients who would not be considered during the LAS-dependent allocation. The majority of our COPD patients underwent SLTX, which was associated with higher mortality, when compared with BLTX. This is well known and not novel per se [9, 10] . We have also identified SLTX to be a significant predictor for the development of bronchiolitis obliterans syndrome and death [11] . Although we will have to carefully reconsider the use of SLTX in COPD patients, the dramatic organ shortage at the moment may still justify SLTX. Obviously, SLTX may allow transplantation of 2 candidates with a single-donor lung package, potentially allowing acceptable cumulative survival and life quality. Further, SLTX may be considered due to the relatively lower surgical risk/trauma in selected high-risk patients when factors such as advanced age, relevant comorbidities, redo procedures or anatomical obstacles render BLTX too high a risk.
In contrast to previous data, we did not detect significantly reduced overall waiting times of transplanted patients within the 5 years after the LAS implementation. This may be explained by the relatively small number and heterogeneity of patients in this single-centre analysis. The latter may also explain why we did not detect a reduction in waitlist mortality.
CF represents the third most frequent diagnosis in patients undergoing lung transplantation at our centre and also in the USA [12] . Larger cohorts have reported on benefits for patients with CF under the LAS system, similar to patients with ILD [8, 13] . Gottlieb et al. [6] presented data incorporating all lung transplant recipients in Germany 1 year after introduction of the LAS and noted a shift in transplanted CF patients of + 26%, when compared with the pre-LAS system. In contrast to the latter data, lung transplantations in CF patients were even slightly reduced in our centre, although CF patients presented with higher pretransplant LAS scores and a listing frequency comparable to that of ILD patients. Possibly, CF patients are less likely allocated seemingly appropriate donor lungs considering the relatively young age and small size in this group. Additionally, CF patients are regularly listed for BLTX only due to their relatively young age and chronic infections. Both COPD and ILD patients may be evaluated for SLTX and BLTX. However, the LAS does not seem disadvantageous for CF patients as they exhibited the highest posttransplant survival probability.
An LAS of greater than 50 was associated with higher posttransplant mortality in several studies [14, 15] . In fact, urgency gains more weight for patients with an LAS of greater than 50, and the presumably worse clinical condition in such patients may adversely affect transplant outcome. Our present data, however, did not support such previous findings, but relatively low numbers of high-LAS patients in this analysis may be the reason why the Kaplan-Meier survival estimation predicted similar outcomes in low-and high-LAS patients.
LIMITATIONS
Our study describes a retrospective, single-centre experience.
Further multicentre analyses, incorporating large cohorts and taking quality of life into account, are required to assess the effect of the LAS on long-term outcomes outside of the USA more precisely.
CONCLUSION
In summary, this study presents favourable novel long-term data on the effects and utility of the LAS implementation on lung transplantation in Germany.
